Mutation or loss of Wilms' tumor gene 1 (WT1) are not major reasons for immune escape in patients with AML receiving WT1 peptide vaccination

Inoue K, Ogawa H, Sonoda Y, Kimura T, Sakabe H, Oka Y, Miyake S, Tamaki H, Oji Y, Yamagami T: Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia. Blood. 1997, 89: 1405-1412.

Menssen HD, Renkl HJ, Rodeck U, Maurer J, Notter M, Schwartz S, Reinhardt R, Thiel E: Presence of Wilms' tumor gene (wt1) transcripts and the WT1 nuclear protein in the majority of human acute leukemias. Leukemia. 1995, 9: 1060-1067.

Miwa H, Beran M, Saunders GF: Expression of the Wilms' tumor gene (WT1) in human leukemias. Leukemia. 1992, 6: 405-409.

Nakatsuka S, Oji Y, Horiuchi T, Kanda T, Kitagawa M, Takeuchi T, Kawano K, Kuwae Y, Yamauchi A, Okumura M: Immunohistochemical detection of WT1 protein in a variety of cancer cells. Mod Pathol. 2006, 19: 804-814.

Sugiyama H: Cancer immunotherapy targeting WT1 protein. Int J Hematol. 2002, 76: 127-132. 10.1007/BF02982574.

Oka Y, Tsuboi A, Oji Y, Kawase I, Sugiyama H: WT1 peptide vaccine for the treatment of cancer. Curr Opin Immunol. 2008, 20: 211-220. 10.1016/j.coi.2008.04.009.

Rezvani K, Yong AS, Mielke S, Savani BN, Musse L, SUperata J, Jafapour B, Boss C, Barrett AJ: Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood. 2008, 111: 236-242. 10.1182/blood-2007-08-108241.

Keilholz U, Letsch A, Busse A, Asemissen AM, Bauer S, Blau IW, Hofmann WK, Uharek L, Thiel E, Scheibenbogen C: A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. Blood. 2009, 113: 6541-6548. 10.1182/blood-2009-02-202598.

Gajewski TF, Meng Y, Harlin H: Immune suppression in the tumor microenvironment. J Immunother. 2006, 29: 233-240. 10.1097/01.cji.0000199193.29048.56.

Seliger B: Strategies of tumor immune evasion. BioDrugs. 2005, 19: 347-354. 10.2165/00063030-200519060-00002.

Kim R, Emi M, Tanabe K: Cancer immunoediting from immune surveillance to immune escape. Immunology. 2007, 121: 1-14. 10.1111/j.1365-2567.2007.02587.x.

Slingluff CL, Colella TA, Thompson L, Graham DD, Skipper JC, Caldwell J, Brinckerhoff L, Kittlesen DJ, Deacon DH, Oei C: Melanomas with concordant loss of multiple melanocytic differentiation proteins: immune escape that may be overcome by targeting unique or undefined antigens. Cancer Immunol Immunother. 2000, 48: 661-672. 10.1007/s002620050015.

Singh R, Paterson Y: Immunoediting sculpts tumor epitopes during immunotherapy. Cancer Res. 2007, 67: 1887-1892. 10.1158/0008-5472.CAN-06-3960.

Seifert U, Liermann H, Racanelli V, Halenius A, Wiese M, Wedemeyer H, Ruppert T, Rispeter K, Henklein P, Sijts A: Hepatitis C virus mutation affects proteasomal epitope processing. J Clin Invest. 2004, 114: 250-259.

Theobald M, Ruppert T, Kuckelkorn U, Hernandez J, Haussler A, Ferreira EA, Liewer U, Biggs J, Levine AJ, Huber C: The sequence alteration associated with a mutational hotspot in p53 protects cells from lysis by cytotoxic T lymphocytes specific for a flanking peptide epitope. J Exp Med. 1998, 188: 1017-1028. 10.1084/jem.188.6.1017.

Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S: Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol. 2000, 74: 181-273. full_text.

Algarra I, Cabrera T, Garrido F: The HLA crossroad in tumor immunology. Hum Immunol. 2000, 61: 65-73. 10.1016/S0198-8859(99)00156-1.

Watson NF, Ramage JM, Madjd Z, Spendlove I, Ellis IO, Scholefield JH, Durrant LG: Immunosurveillance is active in colorectal cancer as downregulation but not complete loss of MHC class I expression correlates with a poor prognosis. Int J Cancer. 2006, 118: 6-10. 10.1002/ijc.21303.

Seliger B, Atkins D, Bock M, Ritz U, Ferrone S, Huber C, Storkel S: Characterization of human lymphocyte antigen class I antigen-processing machinery defects in renal cell carcinoma lesions with special emphasis on transporter-associated with antigen-processing down-regulation. Clin Cancer Res. 2003, 9: 1721-1727.

Seliger B, Maeurer MJ, Ferrone S: Antigen-processing machinery breakdown and tumor growth. Immunol Today. 2000, 21: 455-464. 10.1016/S0167-5699(00)01692-3.

Garcia-Lora A, Martinez M, Algarra I, Gaforio JJ, Garrido F: MHC class I-deficient metastatic tumor variants immunoselected by T lymphocytes originate from the coordinated downregulation of APM components. Int J Cancer. 2003, 106: 521-527. 10.1002/ijc.11241.

Siehl JM, Thiel E, Heufelder K, Snarski E, Schwartz S, Mailander V, Keilholz U: Possible regulation of Wilms' tumour gene 1 (WT1) expression by the paired box genes PAX2 and PAX8 and by the haematopoietic transcription factor GATA-1 in human acute myeloid leukaemias. Br J Haematol. 2003, 123: 235-242. 10.1046/j.1365-2141.2003.04622.x.

King-Underwood L, Pritchard-Jones K: Wilms' tumor (WT1) gene mutations occur mainly in acute myeloid leukemia and may confer drug resistance. Blood. 1998, 91: 2961-2968.

Summers K, Stevens J, Kakkas I, Smith M, Smith LL, Macdougall F, Cavenagh J, Bonnet D, Young BD, Lister TA, Fitzgibbon J: Wilms' tumour 1 mutations are associated with FLT3-ITD and failure of standard induction chemotherapy in patients with normal karyotype AML. Leukemia. 2007, 21: 550-551. 10.1038/sj.leu.2404514. author reply 552

Chang CC, Ferrone S: Immune selective pressure and HLA class I antigen defects in malignant lesions. Cancer Immunol Immunother. 2007, 56: 227-236. 10.1007/s00262-006-0183-1.